Ticker brief
NVAX NOVAVAX INC
Consumer, Non-cyclical · Biotechnology
last close
$9.26
1 day
+2.3%
14 days
+15.0%
mkt cap
$1.6B
signals 14d
19
authors 14d
17
crowd 14d
+0.8σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 55% cheap · 1 pctile own 1y | IV/HV 0.99× (as of 2026-08-06) |
| Skew — 25Δ RR 30d | +0.023 24 pctile own 1y | balanced vs own range |
| Net dealer OI (NDOI) | +1.26 thin | 5-session Δ -1.47 (as of 2026-07-16) |
| OI alarm | quiet | last alarm 2025-05-20 (z=5.2) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-19 → 2026-08-28 · now +0.47 (−1 bearish … +1 bullish)
Who spoke17
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @StockPatternPro | C | -0.32 | 2 | +0.45 |
| @42traders | B | -0.60 | 2 | +0.45 |
| @UltimateTrad8r | C | +0.49 | 1 | +0.20 |
| @TrendSpider | C | -1.01 | 1 | +0.30 |
| @LongGameEquity | B | +0.30 | 1 | +0.35 |
| @JensKlattFX | B | +0.50 | 1 | +0.10 |
| @Brad_E_Schulz | C | · | 1 | +0.50 |
| @chad_ventures | C | -1.84 | 1 | +0.20 |
| @Biomaven | A | +1.79 | 1 | +0.55 |
| @cfaryanoconnell | C | -1.48 | 1 | +0.00 |
| @ClassicRoy | C | -1.52 | 1 | +0.00 |
| @FlowbyBobby | C | · | 1 | +0.50 |
| @TheNewMoney_app | C | · | 1 | +0.35 |
| @thesetupfactory | B | -1.25 | 1 | +0.35 |
| @CrweWorld | C | · | 1 | +0.50 |
| @BiopharmIQ | B | · | 1 | +0.40 |
| @EmmanuelInvest | C | -1.11 | 1 | +0.50 |
Recent signals19of 19 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @EmmanuelInvest | +0.50 | Partners received updated Nuvaxovid approvals in the US, EU and Japan for the 2026-27 season. | — | tweet ↗ |
| 2026-08-28 | @BiopharmIQ | +0.40 | Biotech open summary pairs stock moves with clinical, regulatory and financing events | — | tweet ↗ |
| 2026-08-28 | @CrweWorld | +0.50 | Novavax reported Nuvaxovid approvals in the US, EU and Japan for the 2026-2027 vaccination season. | — | tweet ↗ |
| 2026-08-25 | @thesetupfactory | +0.35 | Expresses positive approval of NVAX, with supporting context in media. | -1.9% | tweet ↗ |
| 2026-08-25 | @TheNewMoney_app | +0.35 | Reports $110,000 of NVAX $14 calls purchased for April 2027. | -1.9% | tweet ↗ |
| 2026-08-25 | @FlowbyBobby | +0.50 | Reports an $84K purchase of NVAX calls. | -1.9% | tweet ↗ |
| 2026-08-24 | @ClassicRoy | +0.00 | Identifies options with increasing implied volatility. | +4.5% | tweet ↗ |
| 2026-08-24 | @cfaryanoconnell | +0.00 | Lists options with increasing implied volatility. | +4.5% | tweet ↗ |
| 2026-08-24 | @Biomaven | +0.55 | Endorses Novavax's Nuvaxovid as the preferred booster. | +4.5% | tweet ↗ |
| 2026-08-22 | @chad_ventures | +0.20 | Congratulates a member on a completed successful NVAX trade. | +3.6% | tweet ↗ |
| 2026-08-21 | @StockPatternPro | +0.65 | NVAX remains on track to exceed $11. — Reaffirms a forward price objective above $11. | +3.6% | tweet ↗ |
| 2026-08-21 | @Brad_E_Schulz | +0.50 | Lists intraday leaders up at least 4% on at least 1.5 times average volume. | +3.6% | tweet ↗ |
| 2026-08-21 | @42traders | +0.80 | Added again to existing NVAX shares and 2028 LEAPS positions. — Explicitly adds to long-term NVAX equity and LEAPS holdings. | +3.6% | tweet ↗ |
| 2026-08-20 | @JensKlattFX | +0.10 | Maps public cancer-vaccine peers, sympathy moves, clinical prospects, and M&A potential | +10.0% | tweet ↗ |
| 2026-08-19 | @LongGameEquity | +0.35 | Uses broad daily gains to argue that SaaS, retail and pharma rotation is strengthening. | +5.3% | tweet ↗ |
| 2026-08-19 | @42traders | +0.10 | Discloses accumulated PFE shares and maps a breakout with resistance near 31.50 and a gap at 31.27. | +5.3% | tweet ↗ |
| 2026-08-19 | @TrendSpider | +0.30 | AI scan identifies public companies advancing mRNA technology after a cancer-vaccine breakthrough. | +5.3% | tweet ↗ |
| 2026-08-19 | @StockPatternPro | +0.25 | Reports successful MRNA trial news and notes NVAX moving higher in sympathy. | +5.3% | tweet ↗ |
| 2026-08-19 | @UltimateTrad8r | +0.20 | Reports a completed LULU sale and lists reaction names being watched after the MRNA move. | +5.3% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.